Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

GeneSoft: The Value of Compromised Products

This article was originally published in Start Up

Executive Summary

Following the FDA's rejection of Factive, GlaxoSmithKline gave it back to its Korean owner, LG Life Sciences Now the compromised--and newly approved--product is the basis for a start-up's spectacular return from a near-death experience--and the latest in a string of biotech successes based around products the previous owners had rejected.
Advertisement

Related Content

In-Licensing: Still a Difficult Model
In-Licensing: Still a Difficult Model
Amdipharm: From Pharmacist to Pharma Firm
Arrow: Focus and Flexibility
Can In-Licensing Models Substitute for Discovery?
EyeTech: Primary Care Dollars for Specialty Pharma
The Infrastructure Dilemma
GPC: A Model for the Rest of Us
GPC: A Model for the Rest of Us
Anti-Infective Risk Reduction: GeneSoft Skips to the Clinic

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC090741

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel